Jordi Dorca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6289651/publications.pdf

Version: 2024-02-01

108	6,499	43	78
papers	citations	h-index	g-index
118	118	118	6199
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Radio-Histological Correlation of Lung Features in Severe COVID-19 Through CT-Scan and Lung Ultrasound Evaluation. Frontiers in Medicine, 2022, 9, 820661.	1.2	4
2	Silicone Stent Versus Fully Covered Metallic Stent in Malignant Central Airway Stenosis. Annals of Thoracic Surgery, 2021, 111, 283-289.	0.7	13
3	Mapping <scp>IPF</scp> helps identify geographic regions at higher risk for disease development and potential triggers. Respirology, 2021, 26, 352-359.	1.3	18
4	Experience With Nintedanib in Severe Pulmonary Fibrosis Associated With Systemic Sclerosis: A Case Series. Open Respiratory Archives, 2021, 3, 100080.	0.0	3
5	Comparing Probe-Based Confocal Laser Endomicroscopy With Histology. Are We Looking at the Same Picture?. Archivos De Bronconeumologia, 2021, , .	0.4	O
6	Lung Ultrasound Score to Predict Outcomes in COVID-19. Respiratory Care, 2021, 66, 1263-1270.	0.8	12
7	Lung Transplant Improves Survival and Quality of Life Regardless of Telomere Dysfunction. Frontiers in Medicine, 2021, 8, 695919.	1.2	13
8	A prospective study of lung disease in a cohort of early rheumatoid arthritis patients. Scientific Reports, 2020, 10, 15640.	1.6	30
9	Effectiveness of an intensive weight-loss program for severe OSA in patients undergoing CPAP treatment: a randomized controlled trial. Journal of Clinical Sleep Medicine, 2020, 16, 503-514.	1.4	20
10	Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data. Rheumatology International, 2020, 40, 719-726.	1.5	21
11	Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, XpertⓇMTB/RIF. Journal of Infection, 2020, 80, 298-300.	1.7	1
12	Host- and Pathogen-Related Factors for Acute Cardiac Events in Pneumococcal Pneumonia. Open Forum Infectious Diseases, 2020, 7, ofaa522.	0.4	5
13	Imbalance in the Expression of Genes Associated with Purinergic Signalling in the Lung and Systemic Arteries of COPD Patients. Scientific Reports, 2019, 9, 2796.	1.6	3
14	Anthropometrical phenotypes are important when explaining obstructive sleep apnea in female bariatric cohorts. Journal of Sleep Research, 2019, 28, e12830.	1.7	14
15	Ultrathin Bronchoscopy with and without Virtual Bronchoscopic Navigation: Influence of Segmentation on Diagnostic Yield. Respiration, 2019, 97, 252-258.	1.2	19
16	Impact of acute exacerbations on platelet reactivity in chronic obstructive pulmonary disease patients. International Journal of COPD, 2018, Volume 13, 141-148.	0.9	9
17	QuantiFERON-TB Gold In-Tube as a Confirmatory Test for Tuberculin Skin Test in Tuberculosis Contact Tracing: A Noninferiority Clinical Trial. Clinical Infectious Diseases, 2018, 66, 396-403.	2.9	18
18	Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells. BMC Pulmonary Medicine, 2018, 18, 63.	0.8	59

#	Article	IF	CITATIONS
19	Defining the role of neutrophil-to-lymphocyte ratio in COPD: a systematic literature review. International Journal of COPD, 2018, Volume 13, 3651-3662.	0.9	38
20	Positive Airway Pressure to Enhance Computed Tomography Imaging for Airway Segmentation for Virtual Bronchoscopic Navigation. Respiration, 2018, 96, 525-534.	1.2	5
21	Is the purinergic pathway involved in the pathology of COPD? Decreased lung CD39 expression at initial stages of COPD. Respiratory Research, 2018, 19, 103.	1.4	9
22	Consenso multidisciplinar sobre prevención y tratamiento de la tuberculosis en pacientes candidatos a tratamiento biológico. Adaptación al paciente dermatológico. Actas Dermo-sifiliográficas, 2018, 109, 584-601.	0.2	2
23	Addition of hyaluronic acid improves tolerance to 7% hypertonic saline solution in bronchiectasis patients. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661878738.	1.0	11
24	Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994–2014. Emerging Infectious Diseases, 2018, 24, 1091-1094.	2.0	28
25	Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction. Clinical Respiratory Journal, 2017, 11, 859-866.	0.6	10
26	Effectiveness of a Respiratory Day Hospital Program to Reduce Admissions for Exacerbation in Patients with Severe COPD: A Prospective, Multicenter Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 304-310.	0.7	8
27	The microbiome in respiratory medicine: current challenges and future perspectives. European Respiratory Journal, 2017, 49, 1602086.	3.1	194
28	Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994–2015. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1425-1432.	1.3	22
29	Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. Journal of Antimicrobial Chemotherapy, 2017, 72, 547-5553.	1.3	44
30	QuantiFERON®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study. PLoS ONE, 2017, 12, e0183258.	1.1	7
31	Specific IgA against Pseudomonas aeruginosa in severe COPD. International Journal of COPD, 2017, Volume 12, 2807-2811.	0.9	11
32	Vascular disease in COPD: Systemic and pulmonary expression of PARC (Pulmonary and) Tj ETQq0 0 0 rgBT /Ove	rlock 10 T	f 50 222 Td (A
33	Successful Healing of Tracheal Radionecrosis. Chest, 2016, 150, e147-e150.	0.4	4
34	Factors predicting survival in amyotrophic lateral sclerosis patients on non-invasive ventilation. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 337-342.	1.1	27
35	Declining mortality among hospitalized patients with community-acquired pneumonia. Clinical Microbiology and Infection, 2016, 22, 567.e1-567.e7.	2.8	40
36	Colchicine Treatment for Tracheobronchial Amyloidosis. Respiration, 2016, 91, 251-255.	1.2	12

#	Article	IF	Citations
37	Aberrant gene methylation and bronchial dysplasia in high risk lung cancer patients. Lung Cancer, 2016, 94, 102-107.	0.9	1
38	Osificación pulmonar dendriforme en un caso subclÃnico de fibrosis pulmonar familiar. Archivos De Bronconeumologia, 2016, 52, e9-e10.	0.4	3
39	Efficacy and safety of aclidinium/formoterol <i>versus</i> salmeterol/fluticasone: a phase 3 COPD study. European Respiratory Journal, 2016, 48, 1030-1039.	3.1	81
40	Increased AGE-RAGE ratio in idiopathic pulmonary fibrosis. Respiratory Research, 2016, 17, 144.	1.4	40
41	Preclinical lung disease in early rheumatoid arthritis. Chronic Respiratory Disease, 2016, 13, 75-81.	1.0	23
42	Combined Bronchial Artery Embolization and Endobronchial Resection for Bronchial Carcinoid: A Safety and Feasibility Pilot Study. Respiration, 2016, 91, 63-68.	1.2	9
43	Transcutaneous Carbon Dioxide Monitoring in Subjects With Acute Respiratory Failure and Severe Hypercapnia. Respiratory Care, 2016, 61, 428-433.	0.8	13
44	Systemic and Pulmonary Vascular Remodelling in Chronic Obstructive Pulmonary Disease. PLoS ONE, 2016, 11, e0152987.	1.1	20
45	Fibroblast viability and phenotypic changes within glycated stiffened three-dimensional collagen matrices. Respiratory Research, 2015, 16, 82.	1.4	51
46	Transarterial EBUS-TBNA in the Diagnosis of Hilar Lesions. Journal of Bronchology and Interventional Pulmonology, 2015, 22, e19-e22.	0.8	0
47	Personalized Respiratory Medicine: Exploring the Horizon, Addressing the Issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 391-401.	2.5	61
48	Gene and Protein Expression of Fibronectin and Tenascin-C in Lung Samples from COPD Patients. Lung, 2015, 193, 335-343.	1.4	4
49	The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ Open, 2015, 5, e006251-e006251.	0.8	42
50	Roflumilast added to triple therapy in patients with severe COPD: AÂreal life study. Pulmonary Pharmacology and Therapeutics, 2015, 30, 16-21.	1.1	28
51	Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial. PLoS ONE, 2015, 10, e0140202.	1.1	10
52	Impact of pre-hospital antibiotic use on community-acquired pneumonia. Clinical Microbiology and Infection, 2014, 20, O531-O537.	2.8	9
53	Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. Journal of Infection, 2014, 68, 534-541.	1.7	34
54	Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFÎ ² 1. BMC Pulmonary Medicine, 2014, 14, 120.	0.8	77

#	Article	IF	CITATIONS
55	Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e105854.	1.1	45
56	Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 415-423.	1.7	97
57	Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 27-33.	1.7	76
58	Infectious etiology of acute exacerbations inÂsevere COPD patients. Journal of Infection, 2013, 67, 516-523.	1.7	45
59	Clinical Features, Etiology, and Outcomes of Community-Acquired Pneumonia in Patients With Diabetes Mellitus. Medicine (United States), 2013, 92, 42-50.	0.4	35
60	Community-Acquired Legionella pneumophila Pneumonia. Medicine (United States), 2013, 92, 51-60.	0.4	102
61	Rainfall Is a Risk Factor for Sporadic Cases of Legionella pneumophila Pneumonia. PLoS ONE, 2013, 8, e61036.	1.1	47
62	High Prevalence of Left Ventricle Diastolic Dysfunction in Severe COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS ONE, 2013, 8, e68034.	1.1	51
63	Effect of a 3-Step Critical Pathway to Reduce Duration of Intravenous Antibiotic Therapy and Length of Stay in Community-Acquired Pneumonia. Archives of Internal Medicine, 2012, 172, 922-8.	4.3	108
64	Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia. Clinical Microbiology and Infection, 2012, 18, 1149-1155.	2.8	30
65	Repeated Aspergillusisolation in respiratory samples from non-immunocompromised patients not selected based on clinical diagnoses: colonisation or infection?. BMC Infectious Diseases, 2012, 12, 295.	1.3	18
66	Obstructive sleep apnoea and metabolic impairment in severe obesity. European Respiratory Journal, 2011, 38, 1089-1097.	3.1	51
67	Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Critical Care, 2011, 15, R96.	2.5	121
68	Community-Acquired Pneumonia in Patients With Liver Cirrhosis. Medicine (United States), 2011, 90, 110-118.	0.4	78
69	Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clinical Microbiology and Infection, 2011, 17, 1659-1665.	2.8	81
70	Tratamiento endoscópico de la fuga aérea persistente alveolo-pleural con una válvula endobronquial unidireccional. Archivos De Bronconeumologia, 2011, 47, 371-373.	0.4	14
71	Serotypes and genotypes of Streptococcus pneumoniae causing pneumonia and acute exacerbations in patients with chronic obstructive pulmonary disease. Journal of Antimicrobial Chemotherapy, 2011, 66, 487-493.	1.3	38
72	Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2899-2906.	0.4	88

#	Article	IF	CITATIONS
73	Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 1243-1251.	1.3	14
74	Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax, 2010, 65, 77-81.	2.7	97
75	Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. European Respiratory Journal, 2009, 33, 148-152.	3.1	42
76	Risk factors and outcome of communityâ€acquired pneumonia due to Gramâ€negative bacilli. Respirology, 2009, 14, 105-111.	1.3	62
77	Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clinical Microbiology and Infection, 2009, 15, 1033-1038.	2.8	58
78	Manejo endovascular de lesi \tilde{A}^3 n de arteria subclavia izquierda tras toracoplastia por f \tilde{A} stula broncopleural y empiema secundario a Aspergillus fumigatus. Archivos De Bronconeumologia, 2008, 44, 338-340.	0.4	2
79	Early mortality in patients with community-acquired pneumonia: causes and risk factors. European Respiratory Journal, 2008, 32, 733-739.	3.1	105
80	Health Care–Associated Pneumonia Requiring Hospital Admission. Archives of Internal Medicine, 2007, 167, 1393.	4.3	285
81	Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2006, 25, 457-462.	1.3	67
82	Clinical Outcomes for Hospitalized Patients with Legionella Pneumonia in the Antigenuria Era: The Influence of Levofloxacin Therapy. Clinical Infectious Diseases, 2005, 40, 794-799.	2.9	129
83	Outpatient Care Compared with Hospitalization for Community-Acquired Pneumonia. Annals of Internal Medicine, 2005, 142, 165.	2.0	211
84	Contribution of a Urinary Antigen Assay (Binax NOW) to the Early Diagnosis of Pneumococcal Pneumonia. Clinical Infectious Diseases, 2004, 38, 222-226.	2.9	182
85	Bronchiectasis in adult patients: an expression of heterozygosity for CFTR gene mutations?. Clinical Genetics, 2004, 65, 490-495.	1.0	81
86	Incidence and molecular typing of Mycobacterium kansasii in a defined geographical area in Catalonia, Spain. Epidemiology and Infection, 2004, 132, 425-432.	1.0	24
87	Efficacy and Safety of Sequential Amoxicillin-Clavulanate in the Treatment of Anaerobic Lung Infections. European Journal of Clinical Microbiology and Infectious Diseases, 2003, 22, 185-187.	1.3	50
88	Neither questions nor answers, just original data. European Respiratory Journal, 2003, 21, 377.1-377.	3.1	1
89	Molecular Inflammatory Responses Measured in Blood of Patients with Severe Community-Acquired Pneumonia. Vaccine Journal, 2003, 10, 813-820.	3.2	114
90	Title is missing!. Medicine (United States), 2003, 82, 159-169.	0.4	28

#	Article	IF	Citations
91	Clinical Diagnosis of Legionella Pneumonia Revisited: Evaluation of the Community-Based Pneumonia Incidence Study Group Scoring System. Clinical Infectious Diseases, 2003, 37, 483-489.	2.9	63
92	Community-Acquired Pneumonia in Very Elderly Patients. Medicine (United States), 2003, 82, 159-169.	0.4	187
93	Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. European Respiratory Journal, 2002, 19, 944-951.	3.1	62
94	Etiology, Reasons for Hospitalization, Risk Classes, and Outcomes of Communityâ€Acquired Pneumonia in Patients Hospitalized on the Basis of Conventional Admission Criteria. Clinical Infectious Diseases, 2001, 33, 158-165.	2.9	703
95	Usefulness of Betalactam Therapy for Community-Acquired Pneumonia in the Era of Drug-ResistantStreptococcus pneumoniae:A Randomized Study of Amoxicillin-Clavulanate and Ceftriaxone. Microbial Drug Resistance, 2001, 7, 85-96.	0.9	56
96	Prospective Study of the Usefulness of Sputum Gram Stain in the Initial Approach to Communityâ€Acquired Pneumonia Requiring Hospitalization. Clinical Infectious Diseases, 2000, 31, 869-874.	2.9	199
97	Vertebral and Rib Sarcoidosis: Long-Term Clinical Remission with Methotrexate. Clinical Rheumatology, 1999, 18, 492-494.	1.0	23
98	Usefulness of PCR and Antigen Latex Agglutination Test with Samples Obtained by Transthoracic Needle Aspiration for Diagnosis of Pneumococcal Pneumonia. Journal of Clinical Microbiology, 1999, 37, 709-714.	1.8	50
99	Guidelines for management of adult community-acquired lower respiratory tract infections. European Respiratory Journal, 1998, 11, 986-991.	3.1	196
100	Clinical and Epidemiological Findings in Mechanically-Ventilated Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 622-628.	1.3	28
101	Protected bronchoalveolar lavage in the diagnosis of ventilator-associated pneumonia. European Respiratory Journal, 1996, 9, 1500-1507.	3.1	21
102	Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study American Journal of Respiratory and Critical Care Medicine, 1996, 154, 1456-1461.	2.5	177
103	Efficacy, safety, and therapeutic relevance of transthoracic aspiration with ultrathin needle in nonventilated nosocomial pneumonia American Journal of Respiratory and Critical Care Medicine, 1995, 151, 1491-1496.	2.5	53
104	Risk factors for nosocomial Legionella pneumophila pneumonia American Journal of Respiratory and Critical Care Medicine, 1994, 149, 625-629.	2.5	123
105	Fatal lung abscess due to Lactobacillus casei ss rhamnosus Thorax, 1992, 47, 992-992.	2.7	1
106	Needle aspiration techniques in the diagnosis of pneumonia Thorax, 1991, 46, 601-603.	2.7	21
107	EMPIRICAL TREATMENT OF PNEUMOCOCCAL PNEUMONIA IN SPAIN. Lancet, The, 1989, 333, 1338-1339.	6.3	7
108	Risk Factors and Response to Antibiotic Therapy in Adults with Bacteremic Pneumonia Caused by Penicillin-Resistant Pneumococci. New England Journal of Medicine, 1987, 317, 18-22.	13.9	403